Resverlogix

Resverlogix EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Resverlogix (RVX.TO) as of Nov 6, 2026 is -3.85. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -6.18 — a change of -37.67% (higher).

EV/EBIT

-3.85

YoY

-37.67%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Resverlogix is 2025 -3.85 . EV/EBIT (Enterprise Value to EBIT) of Resverlogix was 2024 -6.18 . It decreases by -37.67% higher compared to the previous year.

The Resverlogix EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-517.37 USD
Jan 1, 2019
-0.89 USD
Jan 1, 2020
-1,375.66 USD
Jan 1, 2021
-1.25 USD
Jan 1, 2022
-2.23 USD
Jan 1, 2023
-4.54 USD
Jan 1, 2024
-6.18 USD
Jan 1, 2025
-3.85 USD
The Resverlogix EV/EBIT history
YEAREV/EBITYoY
-3.85-37.67%
-6.18+36.17%
-4.54+103.53%
-2.23+77.70%
-1.25-99.91%
-1,375.66+154,860.71%
-0.89-99.83%
-517.37+107,055.39%
-0.48-17.75%
-0.59-41.40%
-1.00-57.72%
-2.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resverlogix Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Resverlogix's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Resverlogix's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Resverlogix's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Resverlogix grows earnings faster than its peers.

Resverlogix Stock analysis

What does Resverlogix do? Resverlogix Corp is a biopharmaceutical company based in Canada that specializes in the research and development of innovative therapies for cardiovascular diseases. It was founded in 2001 by Dr. Donald J. McCaffrey and has been listed on the Toronto Stock Exchange since 2006. The company focuses on the development of synthetic molecules with the same potential as Resveratrol, a natural compound found in red grapes and wine, for the treatment of cardiovascular diseases. Resverlogix Corp follows an innovative business model that involves identifying disease-causing factors and developing targeted molecules to influence them, with the goal of developing effective therapies for patients with cardiovascular diseases. The company specializes in the development of therapeutic agents for atherosclerosis and diabetic nephropathy, and currently has two main products in clinical development: Apabetalone for the treatment of atherosclerosis and BAC25 for diabetic nephropathy. Apabetalone acts directly on the genome of cells and influences the gene expression of proteins relevant to the development of atherosclerosis, while BAC25 targets glucose and lipid metabolism in the kidney to slow down or prevent the development of diabetic nephropathy. Overall, Resverlogix Corp is a biopharmaceutical company focused on innovative therapies for cardiovascular diseases, with a business model based on identifying disease-causing factors and developing synthetic molecules to target them. Resverlogix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resverlogix stock

EV/EBIT (Enterprise Value to EBIT) of Resverlogix is -3.85 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Resverlogix changed from -6.18 to -3.85, representing a -37.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Resverlogix since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Resverlogix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Resverlogix

All Key Metrics — Resverlogix